Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

NCT04709835 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04709835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04709835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2021
Completion date
October 13, 2021
Enrollment
104 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19